RARX Insider Trading Activity and SEC Form 4 Filings
RARX insider trading summary
No open-market insider purchases or sales of Ra Pharmaceuticals, Inc. (RARX) have been reported on SEC Form 4 in the past 12 months.
Latest RARX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Mar 17, 2020 | Alonso Ricardo | See Remarks | Sell | $101K (2,288 @ $44.25) |
| Mar 16, 2020 | Ramin Farzaneh-Far | Chief Medical Officer | Sell | $479K (10,595 @ $45.16) |
| Feb 18, 2020 | Ramin Farzaneh-Far | Chief Medical Officer | Sell | $494K (10,595 @ $46.61) |
| Jan 17, 2020 | Alonso Ricardo | See Remarks | Sell | $107K (2,285 @ $47.02) |
| Jan 15, 2020 | Ramin Farzaneh-Far | Chief Medical Officer | Sell | $497K (10,595 @ $46.95) |
| Dec 17, 2019 | Alonso Ricardo | See Remarks | Sell | $108K (2,285 @ $47.08) |
| Dec 17, 2019 | Simon Read | Chief Scientific Officer | Sell | $471K (10,000 @ $47.08) |
| Dec 16, 2019 | Ramin Farzaneh-Far | Chief Medical Officer | Sell | $500K (10,595 @ $47.23) |
| Nov 15, 2019 | Ramin Farzaneh-Far | Chief Medical Officer | Sell | $494K (10,595 @ $46.66) |
| Nov 14, 2019 | Simon Read | Chief Scientific Officer | Sell | $467K (10,000 @ $46.68) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.